Clinically qualifying predictive biomarkers of response to PARPi in patients with prostate cancer

by VHIO

PARP inhibitors (PARPi) are approved for treating advanced prostate cancers with various defective DNA repair genes, although not all patients derive the same benefit from this targeted therapy.

Read more

Genetic gene mutations: opening new therapeutic avenues in metastatic prostate cancer

by Vall d’Hebron

DNA-repair gene mutations are found inherited in one out of every ten men with metastatic prostate cancer. International study shows the prognostic and predictive value of these mutations in more prec...

Read more
Subscribe to Directory
Write an Article

Recent News

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Palobiofarma announces the completion th...

by Palobiofarma

Palobiofarma S.L. is pleased to announce the “last patient last visi...

Photos Stream